Abstract
Knowledge of the genetic profile of Cystic Fibrosis (CF) contributes to a better understanding of the genotype/phenotype relationship, particularly in mixed populations such as in Brazil. To describe clinical data of CF patients with rare or not yet observed CFTR gene mutations in Brazil. It was a case series of CF patients followed-up at a referral center. Clinical and laboratory data were obtained through medical records. Molecular analysis of the mutations was performed by conventional methods and/or by next-generation sequencing. Ten patients were studied, seven had five pathogenic mutations without previous description in Brazil (Q1100P, Y109C, A107P, E1409K and K162E), one of which has not yet been reported in patients with CF (A107P). Among the seven patients, three (two siblings) had the second mutant allele of rare occurrence among Brazilians patients (G1069R and 2307insA). Three other patients also had at least one rare variant (V201M, S466X and G1069R). The age of the CF diagnosis ranged from 1 to 190 months in the ten cases and the main clinical manifestations were respiratory symptoms and difficulty in gaining weight. All but one patient presented clinical and/or laboratory data compatible with pancreatic insufficiency. The identification of rare or not yet described CFTR mutations in patients with CF in Brazil highlights the high genetic heterogeneity in this population. Knowledge of the genotypic profile of Brazilian CF patients can contribute to the development of specific mutation panels for the genetic investigation targeting each region of the country, as well as helping to understand the complex genotype/phenotype relationship, especially in mixed populations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Notes
Personal communication, Mendelics Laboratory. The annotation and prediction of pathogenicity was done by the Mendelics laboratory using Abracadabra software as well as consulting the Human Genome Mutation Database and ClinVar Database.
References
Cystic Fibrosis Mutation Database. http://www.genet.sickkids.on.ca/cftr/. Accessed 6 Apr 2018
Bobadilla JL, Macek M Jr, Fine JP, Farrell PM (2002) Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 19(6):575–606
De Boeck K, Amaral MD (2016) Progress in therapies for cystic fibrosis. Lancet Respir Med 4(8):662–674
Mota LR, Souza EL, Rocha PHSA, Vieira MJF, dos Santos JF, Lage VMGB et al (2015) Estudos genéticos sobre a fibrose cística no brasil: uma revisão sistemática. Rev Ciênc Méd Biol 14(2):238–245
Brazilian Cystic Fibrosis Registry (REBRAFC)—Patient Registry 2015. http://portalgbefc.org.br/wp-content/uploads/2017/11/Registro2015_Ingles.pdf. Accessed 5 Apr 2018
Abe-Sandes K, Bomfim TF, Machado TMB, Abe-Sandes C, Acosta AX, Alves CRB et al (2010) Genomic ancestry, socioeconomic status and vulnerability to HIV/AIDS in Bahia, Brazil. Saude Soc 19(2):75–84
Mota LR, de Castro LL, da Anunciação Ferreira T, de Lima RL, Toralles MB, Souza EL (2018) Cystic fibrosis: identification and frequency of mutations in a mixed population from a low-income region in Northeastern Brazil. Pediatr Pulmonol 53:1006–1008
Chillon M, Casals T, Gimenez J, Ramos MD, Palacios A, Morral N et al (1994) Analysis of the CFTR gene confirms the high genetic heterogeneity of the Spanish population: 43 mutations account for only 78% of CF chromosomes. Hum Genet 93:447–451
Schaedel C, Kristoffersson A-C, Kornfalt R, Holmberg L (1994) A novel cystic fibrosis mutation, Y109C, in the first transmembrane domain of CFTR. Hum Mol Genet 3:1001–1002
Chillón M, Casals T, Mercier B, Bassas L, Lissens W, Silber S et al (1995) Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 332(22):1475–1480
Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG (1993) Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 3:151–156
Sort Intolerant From Tolerant—SIFT. http://sift.jcvi.org/. Accessed 5 Apr 2018
Polymorphism Phenotyping 2—PolyPhen2. http://genetics.bwh.harvard.edu/pph2/. Accessed 5 Apr 2018
1000 Genomes Project. http://www.internationalgenome.org/. Accessed 5 Apr 2018
ExAC Brownser Beta. http://exac.broadinstitute.org. Accessed 5 Apr 2018
NHLBI Exome Sequencing Project. http://evs.gs.washington.edu/EVS/. Accessed 5 Apr 2018
Hopf TA, Ingraham JB, Poelwijk FJ, Schärfe COI, Springer M, Sander C et al (2017) Mutation effects predicted from sequence co-variation. Nat Biotecnol 35(2):128–139
Rana-Diez P, Colon C, Alonso-Fernandez JR, Solar A, Barros-Tizon JC, Barros-Casas D et al (2008) Three novel mutations in the CFTR gene identified in Galician patients. J Cyst Fibros 7:520–522
Rozen R, Ferreira-Rajabi L, Robb L, Colman N (1995) L206W mutation of the cystic fibrosis gene, relatively frequent in French Canadians, is associated with atypical presentations of cystic fibrosis. Am J Med Genet 57:437–439
Clain J, Lehmann-Che J, Duguépéroux I, Arous N, Girodon E, Legendre M et al (2005) Misprocessing of the CFTR protein leads to mild cystic fibrosis phenotype. Hum Mutat 25:360–371
Faucz FR, Gimenez J, Ramos MD, Pereira-Ferrari L, Estivill X, Raskin S et al (2007) Cystic fibrosis in a southern Brazilian population: characteristics of 90% of the alleles. Clin Genet 72:218–223
Bernardino ALF, Ferri A, Passos-Bueno MR, Kim CEA, Nakaie CMA, Gomes CET, Damaceno N et al (2000) Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. Genet Test 4(1):69–74
Furlan LL, Ribeiro JD, Bertuzzo CS, Salomão Junior JB, Souza DR, Marson FA (2017) Variants in the interleukin 8 gene and the response to inhaled bronchodilators in cystic fibrosis. J Pediatr (Rio J) 93:639–648
Brazilian Cystic Fibrosis Registry (REBRAFC)—Patient Registry 2014. http://portalgbefc.org.br/wp-content/uploads/2017/11/Registro2014_Ingles.pdf. Accessed 5 Apr 2018
Lopes-Pacheco M (2016) CFTR modulators: shedding light on precision medicine for cystic fibrosis. Front Pharmacol 7:275
IBGE (Instituto Brasileiro de Geografia e Estatística). Brazilian census (2010) http://www.ibge.gov.br/. Accessed 1 Aug 2018
Acknowledgements
To parents and patients who agreed to participate in this study and to the Brazilian Cystic Fibrosis Study Group for making sequencing available to the patients of this center.
Funding
Our study was funded by Foundation for Research Support of the State of Bahia (FAPESB—PPSUS 020/2013) and Brazilian Group of Studies on Cystic Fibrosis (GBEFC).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None of the authors has any conflict of interest to disclose.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Teaching Hospital Professor Edgard Santos research ethics committee (protocol 121/2011). We have read the Journal’s position about ethical standards and affirm that this report is consistent with the guidelines in the Committee on Publication Ethics (COPE).
Informed consent
Informed consent form was signed by each participant or their legal representative.
Rights and permissions
About this article
Cite this article
Mota, L.R., de Melo Filho, V.M., de Castro, L.L. et al. Description of rare mutations and a novel variant in Brazilian patients with Cystic Fibrosis: a case series from a referral center in the Bahia State. Mol Biol Rep 45, 2045–2051 (2018). https://doi.org/10.1007/s11033-018-4361-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-018-4361-y